CD28 and neoplasm: The biomimetic nanoparticle could bypass the step of traditional APC‐mediated antigen processing and directly activate antigen‐specific T cells through the engagement of the cognate T cell receptor and CD28, therefore successfully inhibiting tumor growth in both prophylactic and therapeutic tumor models.[78]